FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant

July 6, 2026 6:50 AM

Pharvaris (Nasdaq: PHVS) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for deucrictibant immediate-release ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found